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Introduction
Hyperuricaemia, deﬁ   ned as a plasma concentration of 
urate (used interchangeably with uric acid) greater than 
0.42 mmol/L (7.0 mg/dL) [1], is the major risk factor for 
gout. Impaired renal clearance of urate, or ‘under-
excretion’, accounts for up to 90% of hyperuricaemia cases. 
In the remainder, the mechanism is excessive production 
of urate due to purine synthetic enzymatic abnormalities, 
haematological malignancies [2] or dietary excess. Under-
excretion and over-production of urate can co-exist [3].
Investigation of the molecular basis of low renal urate 
clearance ought to be conducted in individuals where low 
clearance has been proven but most studies have used 
hyperuricaemia alone as the inclusion criterion, thereby 
reducing the power of the study [4-7].
Simkin and colleagues proposed a spot morning urine 
test of urate excretion normalised to glomerular ﬁ  ltration 
rate (GFR) to identify ‘over-producers’ of urate [8]. We 
propose an amendment to the Simkin Index in order to 
focus upon abnormalities in renal tubular urate transport 
causal for ‘under-excretion’ of urate. We suggest that 
renal uric acid clearance be normalised to the individual’s 
GFR, as estimated by the creatinine clearance, to give the 
fractional clearance of urate (FCU). FCU has been used 
in physiological studies but usually employing 24-hour 
collections of urine [3,6]. We propose that FCU 
calculated from spot urine samples be used as the 
inclusion criterion in studies examining the genetic basis 
for relatively low renal clearance of urate. A renal 
lesion(s) that reduces the ability of the kidney to clear 
uric acid, but not creatinine, will manifest as a low FCU 
relative to normal.
FCU is calculated using the formula:
                                              UUA
 Pcreat
                               FCU =                       
                                              PUA
 Ucreat
By contrast, the Simkin Index does not include plasma 
urate concentrations:
                                                                 Pcreat
                          Simkin Index = UUA
           
                                                                Ucreat
Th  e concentrations of plasma and urinary creatinine 
(Pcreat;  Ucreat) and urate (PUA;  UUA) are readily obtained. 
Measurement of the volume of urine is not required, 
which is a signiﬁ   cant practical advantage [8]. When 
calculated from a morning spot collection (9 to 11 a.m.), 
the Simkin Index was found to be reproducible, the 
coeﬃ   cient of variation being ±20% in 19 normal males 
and closely correlated with their 24-hour urinary uric 
acid outputs [8]. We have found a coeﬃ   cient of variation 
of FCU of ±7% from daytime spot urine collections in 12 
healthy volunteers [9].
Under-excretion or low renal clearance of uric acid
Optimally, when searching for the molecular basis of the 
renal tubular lesion(s) responsible for reduced renal 
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otherwise normal renal function or GFR should be 
studied. Renal impairment alone reduces the renal 
clearance of uric acid. FCU can determine the contri-
bution of renal impairment to the reduced renal 
clearance of uric acid by adjusting for the individual’s 
GFR. Also, FCU is superior to the measurement of the 
renal uric acid clearance alone because it is not aﬀ  ected 
by incomplete urine collections. A caveat is that as renal 
function declines the FCU tends to increase somewhat 
because the renal clearance of urate does not decline as 
rapidly as the creatinine clearance and GFR. In those 
with a GFR between 20 and 30 mL/minute, the mean 
FCU was 0.188 (n = 10) compared to 0.099 in those with 
normal renal function (n = 20) [7]. Th  is eﬀ  ect of poor 
renal function should not be a drawback to using the 
FCU, as mechanistic studies would be better undertaken 
in those with normal GFR.
The genetic ‘lesion’
Renal function (measured by GFR) of many hyper-
uricaemic individuals, especially in the early stages of 
their hyperuricaemia or in the absence of co-morbidities 
such as diabetes, is normal, indicating their FCU will be 
low compared to urate over-producers and most normo-
uricaemic individuals. Hyperuricaemia is common, so 
there is a relatively common renal tubular lesion(s) mani-
fest by an impaired ability of the kidneys to clear uric 
acid. Th   is lesion likely has a genetic basis given that the 
heritability of relatively low FCU has been estimated to 
be 87% [10]. Increasingly, polymorphisms of genes 
encoding transporters relevant for uric acid tubular 
trans  port, such as SLC2A9 and/or ABCG2, have been 
identi ﬁ   ed and are suspected of leading to low FCU 
[4-7,11]. Despite this, FCU has only rarely been used as 
the phenotypic expression of the activity of uric acid 
transporters in clinical studies exploring the genetic basis 
of hyperuricaemia. Vitart and colleagues [6] did not ﬁ  nd 
a correlation between FCU and polymorphisms of 
SLC2A9; however, using FCU enhanced the power of the 
study to potentially discover relevant genetic poly-
morphisms. Th  ese subjects with normal GFR but low 
FCU provide the optimal cohort for studies elucidating 
the molecular and genetic mechanisms for hyper-
uricaemia due to abnormal renal tubular transport of 
urate.
Advantages of using FCU
In an individual who is hyperuricaemic and with renal 
impairment or who over-produces urate, FCU may be 
normal or increased [12]; that is, the mechanism for the 
hyperuricaemia does not include a genetically based, renal 
tubular transport defect. Employing the FCU will eliminate 
patients with these other causes of hyper  uricaemia.
FCU is easily obtained in the clinical setting because a 
simple, random spot urine sample is suﬃ   cient  for  its 
calculation [8]. Collection of the spot sample in the 
morning is recommended [8] to account for any diurnal 
variation in renal function. In fact, FCU decreases during 
sleep when there is a state of relative dehydration 
associated with activation of the renin-angiotensin 
system. FCU is also reduced in some individuals with the 
metabolic syndrome, again possibly due to activation of 
the renin-angiotensin system, and is aﬀ  ected by gross 
changes in hydration status, increasing with signiﬁ  cant 
water loading [13,14].
Graessler and colleagues [15] used 0.06 as the lower 
limit of normal FCU but it is unclear how this level was 
established and population studies, including individuals 
with renal impairment, are required to better establish 
normal ranges for FCU.
Conclusion
It is proposed that FCU represents a good phenotypic 
measure of the ability of the kidney to clear uric acid. A 
mid-morning spot urine sample in a normally hydrated 
individual replaces the inconvenient and often inaccurate 
24-hour urinary uric acid excretion test. Population 
studies of FCU values with attention to demographics, 
co-morbidities, GFR and concomitant medica  tions are 
needed. Use of FCU in genetic studies exploring risk 
factors for hyperuricaemia of renal tubular origin will 
provide more power to identify relevant associations, 
potential mechanisms and, ulti  mately, new therapeutic 
options.
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